Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders
September 27 2019 - 2:32PM
Dow Jones News
By Michael Dabaie
Roche Holding AG's (RHHBY) Genentech said the U.S. Food and Drug
Administration approved Rituxan, in combination with
glucocorticoids, for the treatment of granulomatosis with
polyangiitis and microscopic polyangiitis in pediatric patients 2
years of age and older.
GPA and MPA are rare, potentially life-threatening diseases
affecting small- and medium-sized blood vessels.
This approval is the first pediatric indication for Rituxan,
Genentech said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 27, 2019 14:17 ET (18:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024